Newborn screening identified a Chinese-Canadian infant who was positive for possible β-thalassemia (β-thal). Detailed family studies demonstrated that the proband was a compound heterozygote for the Chinese G γ( A γδβ) 0 -thal deletion and a novel frameshift mutation within exon 3 ( HBB :c.336dup), and heterozygous for the Southeast Asian α-thal deletion (-- SEA /αα). This case illustrates the importance of follow-up molecular testing of positive newborn screening results to confirm the diagnosis and define risks for future pregnancies.